OBJECTIVES: Parkinson’s disease (PD) is a chronic multifaceted neurodegenerative disorder of adult onset which affects quality of life, and places a burden on patients, caregivers and society. In early disease, dopaminergic therapy improves motor symptoms but as the disease progresses, symptoms tend to increase in frequency and severity independent of treatment. Deep brain stimulation (DBS) becomes an option for certain patients but cost becomes an important issue. We performed a systematic review of the literature of economic studies of the use of DBS in patients with PD, including costs studies or economic evaluations expressed as cost per improvement in quality life, decrease in dose of pharmacological treatments or the decrease of carer burden. METHODS: We reviewed the following databases: Medline/Pubmed, Embase, Cochrane Database of Systematic Reviews, LILACS, Cochrane Central Register of Controlled Trials, WHO International Clinical Trials Registry Platform ICTRP portal and ClinicalTrials.gov from 1980 to 2015. RESULTS: From the original 2120 references retrieved, CONCLUSIONS: DBS is a cost-effective intervention for patients with advanced PD but has a high initial cost compared to BMT. However, DBS reduces costs on pharmacological treatment and evidence suggests it also reduces direct, indirect and social costs of PD on the long term.